Companies: 10,795·Total market cap: $144.5T
Tekla Life Sciences Investors

Tekla Life Sciences Investors

HQLNYSEFinancial Services● Active
$17.04
+$0.10(+0.59%)
Market Cap$518152320
P/E Ratio
52W High$18.46
52W Low$12.34

Tekla Life Sciences Investors (HQL) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

HQL · cash on hand · updated Sep 30, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$75,538
FY · as of Sep 30, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$75,538
cashAndCashEquivalents
Short-Term Investments
$0
shortTermInvestments
YoY Change vs Prior Year
vs prior fiscal year
Latest Quarter
$75,538
Q3 2025
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: September 30, 2025

Net cash vs debt

Cash & ST Investments$75,538Cash on Hand
Total Debt$0Total Debt
Net Cash / Net Debt+$75,538Net Cash Position
Cash vs Debt Ratio
Cash 100%Debt 0%

Tekla Life Sciences Investors has a net cash position of $75,538, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$75,538$0 = +$75,538

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
HQL annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Sep 30, 2025Latest$0.1M
Sep 30, 2024$0.0M-100.0%
Sep 30, 2023$15.2M+3425175.7%
Sep 30, 2022$0.0M-55.1%
Sep 30, 2021$0.0M-100.0%
HQL cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Financial Services Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
JPMorgan Chase & Co.
JPMorgan Chase & Co.
JPM
$1.48T176.8%
#2
Berkshire Hathaway Inc.
Berkshire Hathaway Inc.
BRK-A
$373.31B35.4%
#3
Visa Inc.
Visa Inc.
V
$21.99B3.5%
#4
Mastercard Incorporated
Mastercard Incorporated
MA
$10.90B2.5%
#5
Tekla Life Sciences Investors
Tekla Life Sciences InvestorsYOU
HQL
$0.1M0.0%
Financial Services sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Tekla Life Sciences Investors (HQL) cash on hand as of September 30, 2025 is $75,538, comprising $75,538 in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Tekla Life Sciences Investors cash and short-term investments on the balance sheet (10-K filing). Also referred to as Tekla Life Sciences Investors cash reserves or cash position.

Tekla Life Sciences Investors annual cash on hand history shows decreased — in 2025: decreased — in 2025. Tekla Life Sciences Investors cash reserves in 2025 reflect the company's capital allocation strategy.

Tekla Life Sciences Investors carries total debt of $0 against cash of $75,538, resulting in a net cash position of +$75,538. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Frequently asked questions

HQL cash on hand · 5 questions

As of September 30, 2025, Tekla Life Sciences Investors (HQL) has $75,538 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $75,538 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (September 30, 2025): $75,538. Data sourced from the annual 10-K filing via FMP.

HQL cash on handHQL cash reservesHQL cash 2025how much cash does HQL have

Source: FMP /balance-sheet-statement · US GAAP · Tekla Life Sciences Investors · Tekla Life Sciences Investors SEC 10-K & 10-Q filings · US GAAP · Last updated: September 30, 2025